Pasithea Therapeutics Corp. (NASDAQ:KTTA) Sees Large Decrease in Short Interest

Pasithea Therapeutics Corp. (NASDAQ:KTTA) saw a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 8,700 shares, a decline of 67.4% from the February 13th total of 26,700 shares. Currently, 0.9% of the company’s stock are sold short. Based on an average daily trading volume, of 1,030,000 shares, the short-interest ratio is currently 0.0 days.

Pasithea Therapeutics Price Performance

KTTA traded up $0.07 during mid-day trading on Friday, reaching $1.11. 22,587 shares of the stock were exchanged, compared to its average volume of 532,938. Pasithea Therapeutics has a 1 year low of $0.92 and a 1 year high of $9.25. The company has a 50 day moving average price of $1.91 and a two-hundred day moving average price of $3.13.

About Pasithea Therapeutics

Pasithea Therapeutics Corp., a biotechnology company, engages in discovery, research, and development of treatments for central nervous system disorders, RASopathies, and other diseases. Its lead product candidate PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor for use in the treatment of a range of RASopathies, including neurofibromatosis type 1 oncology indications.